{"commentary":{"count":23,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"x_thread":9,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05865990\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TUXEDO-3","nct_id":"NCT05865990","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tuxedo-3-nct05865990. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TUXEDO-3","arms":[{"description":"HER3-DXd will be dosed at 5.6 mg/kg body weight as an intravenous (IV) infusion administered on day 1 (D1) of each 21-day cycle for patients from all cohorts until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.\n\n* Cohort 1: MBC with untreated or progressing BM after local treatment.\n* Cohort 2: aNSCLC with untreated or progressing BM after local treatment.\n* Cohort 3: advanced solid tumor with treatment-naive LMD or LMD progressing after radiotherapy.","label":"Patritumab deruxtecan (HER3-DXd)","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2026-04-03","type":"ACTUAL"},"conditions":["Metastatic Breast Cancer","Advanced Non-Small Cell Squamous Lung Cancer","Solid Tumor, Adult"],"enrollment":{"count":63,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Patritumab deruxtecan","type":"DRUG"}],"last_update":"2026-05-04","lead_sponsor":"MedSIR","official_title":"Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-11-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2.","timeFrame":"From baseline to the date of first documented progression, death from any cause, or treatment discontinuation from any reason, whichever came first, assessed up to 12 months"},{"measure":"Efficacy: Overall survival (OS) rate at 3 months in cohort 3.","timeFrame":"From baseline up to 3 months"}],"references":[{"citation":"Bartsch R, Marhold M, Garde-Noguera J, Gion M, Ruiz-Borrego M, Greil R, Valero M, Llombart-Cussac A, Garcia-Mosquera JJ, Arumi M, Cortes J, Campolier M, Guerrero JA, Slebe F, Martinez-Garcia E, Jimenez-Cortegana C, Vaz-Batista M, Oberndorfer F, Furtner J, Fuereder T, Berghoff AS, Preusser M. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 Nov;26(11):1467-1478. doi: 10.1016/S1470-2045(25)00470-X.","pmid":"41167215","type":"DERIVED"},{"citation":"Fuereder T, Garde-Noguera J, Garcia-Mosquera JJ, Ruiz-Borrego M, Valero M, Llombart-Cussac A, Gion M, Greil R, Arumi M, Campolier M, Guerrero JA, Raimondi G, Mancino M, Jimenez-Cortegana C, Vaz-Batista M, Oberndorfer F, Marhold M, Berghoff AS, Furtner J, Bartsch R, Preusser M. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 Nov;26(11):1454-1466. doi: 10.1016/S1470-2045(25)00465-6.","pmid":"41167214","type":"DERIVED"},{"citation":"Preusser M, Garde-Noguera J, Garcia-Mosquera JJ, Gion M, Greil R, Arumi M, Ruiz-Borrego M, Llombart-Cussac A, Valero M, Cortes J, Campolier M, Guerrero JA, Gonzalez-Alonso P, Jimenez-Cortegana C, Rodriguez-Morato J, Vaz-Batista M, Oberndorfer F, Marhold M, Berghoff AS, Furtner J, Fuereder T, Bartsch R. Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. Nat Med. 2025 Aug;31(8):2797-2805. doi: 10.1038/s41591-025-03744-1. Epub 2025 May 30.","pmid":"40447851","type":"DERIVED"}],"start_date":{"date":"2023-11-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","url":"https://clinicaltrials.gov/study/NCT05865990"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tuxedo-3-nct05865990"}